Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 8:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,082 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Immunodeficiency Virus Type 1 (HIV-1) Clear all
Completed Phase 2 Interventional

Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients

NCT00056641
View directory record Official record
Conditions
HIV Infections
Interventions
tipranavir, ritonavir, saquinavir, amprenavir, lopinavir
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
34
States / cities
Phoenix, Arizona • Berkeley, California • Fountain Valley, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 15, 2026, 8:21 AM EDT
Completed No phase listed Observational

Treatment De-Intensification and Residual HIV-1 in Youth

NCT00867854
View directory record Official record
Conditions
HIV-1, HIV Infections
Interventions
Blood draw
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 15, 2026, 8:21 AM EDT
Active, not recruiting No phase listed Observational

Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients

NCT02390297
View directory record Official record
Conditions
HIV-1 Infection, Receipt of Cal-1 Modified Hematopoietic Cellular Products
Interventions
Blood tests
Genetic
Lead sponsor
Calimmune, Inc.
Industry
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Not applicable Interventional

Effectiveness of Anti-HIV Drugs in Patients Who Have Not Received Previous Anti-HIV Drugs During Different Stages of HIV Infection

NCT00006443
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Nelfinavir mesylate, Lamivudine, Stavudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Phase 3 Interventional

The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs

NCT00002391
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine, Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
3 Months to 12 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • Fort Lauderdale, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Phase 1 Interventional

Combination Drug Treatment of Pediatric HIV Infection

NCT00001818
View directory record Official record
Conditions
HIV Infection
Interventions
Hydroxyurea
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Phase 3 Interventional Results available

TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants

NCT00980538
View directory record Official record
Conditions
HIV Infections, HIV-1
Interventions
Etravirine
Drug
Lead sponsor
Janssen Sciences Ireland UC
Industry
Eligibility
2 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Washington D.C., District of Columbia • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Phase 1 Interventional

Immune and Viral Outcomes of HIV-1 Therapy Interruption

NCT00051818
View directory record Official record
Conditions
HIV Infections
Interventions
Treatment interruption/reinitiation schedule
Behavioral
Lead sponsor
The Wistar Institute
Other
Eligibility
17 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Oct 15, 2026, 8:21 AM EDT
Terminated Not applicable Interventional

Intrauterine Insemination In HIV-Discordant Couples

NCT01173276
View directory record Official record
Conditions
HIV-1, Fertility, Infertility
Interventions
Sperm Washing with Intrauterine Insemination (IUI)
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents

NCT00915655
View directory record Official record
Conditions
HIV-1 Infection
Interventions
darunavir, ritonavir, zidovudine, lamivudine, abacavir
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
12 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Phase 2 Interventional

A Study to Test the Effect of Cyclosporine on the Immune System of Patients With Early HIV Disease

NCT00000880
View directory record Official record
Conditions
HIV Infections
Interventions
Cyclosporine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
12
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults

NCT02599896
View directory record Official record
Conditions
Prevention of HIV Infection, HIV Antibodies, Monoclonal Antibody, Human, Neutralizing Antibody
Interventions
VRC-HIVMAB080-00-AB (VRC01LS), VRC-HIVMAB060-00-AB (VRC01)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP)

NCT03499483
View directory record Official record
Conditions
HIV Prevention
Interventions
bictegravir
Drug
Lead sponsor
Fenway Community Health
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Phase 1 Interventional

White Blood Cell Infusions to Treat HIV Infection

NCT00001647
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infection
Interventions
White blood cell infusion
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

NCT01967940
View directory record Official record
Conditions
HIV, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 15, 2026, 8:21 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

NCT05729568
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Teropavimab, Zinlirvimab, Lenacapavir Tablet, Lenacapavir Injection, Antiretroviral Therapy
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
29
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 15, 2026, 8:21 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection

NCT02842086
View directory record Official record
Conditions
Pre-Exposure Prophylaxis of HIV-1 Infection
Interventions
F/TAF, F/TDF, F/TAF Placebo, F/TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
5,399 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
54
States / cities
Beverly Hills, California • Los Angeles, California • Newport Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 15, 2026, 8:21 AM EDT
Withdrawn Phase 2 Interventional

A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients

NCT00001094
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, Nelfinavir mesylate, Saquinavir, Delavirdine mesylate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
16
States / cities
Menlo Park, California • Stanford, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects

NCT00098722
View directory record Official record
Conditions
HIV Infections
Interventions
Maraviroc (UK-427,857), optimized background therapy
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
62
States / cities
Hobson City, Alabama • Garden Grove, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Phase 3 Interventional Results available

Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

NCT01818596
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
E/C/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
51
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 15, 2026, 8:21 AM EDT
Suspended Phase 3 Interventional

A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

NCT00002362
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Efavirenz, Emtricitabine, Stavudine
Drug
Lead sponsor
Triangle Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
10
States / cities
Sacramento, California • San Francisco, California • Fort Lauderdale, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Islatravir and Methadone Pharmacokinetics (MK-8591-029)

NCT04568603
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Islatravir
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Hollywood, Florida • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Phase 2 Interventional

Safety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People

NCT00078442
View directory record Official record
Conditions
HIV Infections
Interventions
Pegylated interferon alfa-2a
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
3
States / cities
Sacramento, California • Chicago, Illinois • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 7, 2009 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of SPC3 in HIV-1 Infected Patients

NCT00002363
View directory record Official record
Conditions
HIV Infections
Interventions
Peptide Construction 3, Synthetic
Drug
Lead sponsor
Columbia Research Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 8:21 AM EDT